Shares of Threshold Pharmaceuticals (NASDAQ: THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (CELG +0.00%) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.
Threshold's Window of Success Reopens
By Dave Williamson – Jan 23, 2013 at 9:14PM
NASDAQ: CELG
Celgene
Why Threshold popped today.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid